Studies of the Membrane-Protecting Potential of the Combination of 2-Ethyl-6-Methyl-Hydroxypyridine Succinate and Citicoline

Objectives. To assess changes in the phospholipid composition of blood plasma in patients with chronic cerebrovascular disease using the neuroprotectors 2-ethyl-6-methyl-3-hydroxypyridine succinate (Neurox) and citocoline (Neipilept), which are natural metabolites and participants in metabolic processes in the body, alone and in combination. Materials and methods. A total of 40 patients (18 men, 22 women) aged 54–72 years took part in the study; patients had chronic cerebrovascular disease in exacerbation on the background of hypertensive crisis and/or impairments to cardiac rhythm. Results. Extraction of lipids from patients’ blood cells revealed significant reductions in the quantities of all (total) lipids after completion of treatment in patients receiving Neurox, Neipilept, and complex treatment using both agents. Studies of the quantitative composition of blood cell phospholipids showed that there were no significant changes in patients taking Neurox, while citicoline, alone and in combination with 2-ethyl-6-methyl-3-hydroxypyridine succinate, led to increases in total quantities. Assessment of the qualitative composition of classes of phospholipids in plasma showed no significant changes in patients taking Neurox, while those receiving Neipilept alone and with 2-ethyl-6-methyl-3-hydroxypyridine succinate showed significant increases in plasma phosphatidylcholine. There were no significant changes in phosphatidylinositol, phosphatidylserine, or sphingomyelin contents.